News

29% of cisgender men who have sex with men acquired HIV despite being designated as “low risk.”

The monoclonal antibody sotrovimab reduced the risk of hospitalization or death by 85% in high-risk patients with mild-to-moderate COVID-19.

A new study in Israel supports the use of a shorter course of antibiotics for the treatment of complicated urinary tract infection in recipients of kidney transplants.

Incidences of Clostridioides difficile infection have risen in recent years, and understanding risk factors can help practitioners address associated mortality, morbidity and health care costs.

In Gilead’s BICSTaR trial of their full HIV treatment regimen Biktarvy, 97% of treatment-naïve adults and 96% of treatment-experienced adults achieved virological suppression after 1 year.

The emergency use authorization (EUA) is based on the vaccine data and the Food and Drug Administration’s (FDA) Vaccines and Related Biological Products Advisory Committee (VRBPAC) recommendation.

A new report underscores what early data suggested about disparities in the risk of hospitalization and death from COVID-19.

The Walmart-distributed Better Homes & Gardens aromatherapy spray “Lavender & Chamomile with Gemstones” was identified as causing melioidosis in 4 individuals, 2 of whom died.

COVID-19 patients treated with fluvoxamine had a reduced risk of hospitalization and death.

The latest National Immunization Survey-Child, for children born in 2017- 2018, reveals different rates of vaccination by demographic and disease.

Most COVID-19 infection occurs in household settings, and though vaccinated individuals who contracted the Delta variant recovered more quickly than unvaccinated persons, they had similar peak viral load.

The new AY.4.2 "Delta plus" COVID-19 variant is gaining prevalence abroad and is estimated to be slightly more transmissible.

A new study assessed the vaccine acceptance and access among Black and Latinx communities.

First responders are twice as likely to become infected with COVID-19 in the workplace as health care workers and other essential workers, and this increases significantly after adjusting for cofounding factors.

The once-weekly regimen of islatravir and lenacapavir is Merck and Gilead’s first clinical trial since collaborating to develop long-acting HIV treatment options.

The World Health Organization's (WHO) newly formed Scientific Advisory Group on the Origins of Novel Pathogens (SAGO) will lay the groundwork for future identification of future disease threats.

St. Joseph Mercy Health System launched a program in February to provide infusion of monoclonal antibodies for COVID-19 in patients’ homes.

This recommendation was based off of data showing the vaccine was 90% efficacious in this population, and sets the stage for the first COVID-19 vaccine in the age group.

Carbapenem-resistant Klebsiellae was 92.5% susceptible to a combination of ceftibuten (CTB) and VNRX-5236.

Healthcare providers are less likely to prescribe HIV PrEP to Black women, largely due to behavioral stereotyping.

The committee is meeting today to review the data presented to them, and will vote to either recommend or not an Emergency Use Authorization in this pediatric population.

Booster dose eligibility is broadening as the flu season approaches. An expert emphasizes the need to protect for both COVID-19 and the flu in the coming months.

Investigators retrospectively observed 2 communities of essential workers in Toronto, Canada.

Unpublished data from the company's ongoing pediatric trial show children aged 6 to <12 years old have an antibody response greater than that of young adults.

Unapproved stem cell treatments derived from umbilical cord blood can pose potential risks to patients without proven benefits, a CDC study shows.

The median vaccination rate of white American adults was found to be 1.3 times higher than Black and Hispanic adults.

A study presented advocated for combining taniborbactam and cefepime to treat P aeruginosa isolates that develop ESAC phenotypes.

Data presented to the Vaccines and Related Biological Products Advisory Committee (VRBPAC) showed 2 10 µg doses of the Pfizer-BioNTech vaccine to be 90.7% effective in children older than 5 and younger than 12.

The federal agency and infectious disease organization have teamed up to offer a wealth of resources for health care professionals on the frontlines of treating the virus.